Young people are a priority now, not just for the future (BSL-interpreted) @TheLancetTV

The Lancet | Young people are a priority now, not just for the future (BSL-interpreted) @TheLancetTV | Uploaded January 2024 | Updated October 2024, 2 hours ago.
Across the most critical issues impacting health globally – climate change, mental health, research for health and universal health coverage – there is a huge population that is all too often neglected.

Learn more about our 200th Anniversary Spotlights at thelancet.com/lancet-200?dgcid=youtube_video_lancet200_cah

* * *
BSL interpretation by Involve Interpreter, involveinterpreter.co.uk
Watch this film without British Sign Language interpretation: youtu.be/RZ_CXCE9g3o
* * *
Continue this conversation on social! Follow us today at…
Twitter.com/TheLancet
Facebook.com/TheLancetMedicalJournal
Instagram.com/TheLancetGroup
LinkedIn.com/company/The-Lancet

Maternal Health in the Perinatal Period and Beyond (BSL-interpreted)

Bones, moans, and abdominal groans in hyperparathyroidism

Pleuro-peritoneal communication in a patient on dialysis

Advancements in Non-Small Cell Lung Cancer

How to improve access to diagnostics for everyone | The Lancet Commission (BSL-interpreted)

Vertebral artery halo sign in giant cell arteritis

COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma

$Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer Dr James Harding presents the findings of their paper, published in The Lancet Oncology on 2 June 2023: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZONBTC-01): a multicentre, single-arm, phase 2b study. Read the full article here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00242-5/fulltext?dgcid=youtube_video_tlo HER2 is overexpressed or amplified in a subset of biliary tract cancer. Zanidatamab is a bispecific antibody targeting two distinct HER2 epitopes. The results from the study show that Zanidatamab has meaningful clinical benefit with a manageable safety profile in patients with treatment-refractory, HER2-positive biliary tract cancer, supporting its potential use as a future treatment option in HER2-positive biliary tract cancer. Visit The Lancet Oncology at https://www.thelancet.com/journals/lanonc/home?dgcid=youtube_video_tlo Find out more at https://www.thelancet.com/?dgcid=youtube_video_lancet_lancet * * * Continue this conversation on social! Follow us today at… https://Twitter.com/TheLancet & https://Twitter.com/TheLancetOncol https://Instagram.com/thelancetgroup https://Facebook.com/TheLancetMedicalJournal https://LinkedIn.com/company/the-lancet$

The Lancet Commission on medicine, Nazism, and the Holocaust | Global launch event